Several new medical studies have emerged examining various health topics ranging from prescription medications to food industry practices.

Researchers have conducted a study examining the use of popular GLP-1 weight loss medications during early pregnancy, according to findings analyzed by medical experts. These drugs, which have gained widespread popularity for weight management, are being evaluated for their safety profile when used during pregnancy's initial stages.

Separately, scientists have published research indicating that dapagliflozin, a diabetes medication, may reduce the risk of heart failure in individuals with specific genetic variants associated with cardiomyopathy. The study suggests the drug could provide cardiac protection for this particular patient population beyond its primary diabetes management function.

Additional research published in the American Journal of Public Health has detailed connections between ultra-processed foods and the tobacco industry. The study examines similarities in production methods, marketing strategies, and business approaches between tobacco companies and ultra-processed food manufacturers.

Meanwhile, researchers commissioned by the Biden administration have independently released findings from their investigation into alcohol-related health harms. The timing and nature of the release suggests the findings may not align with current U.S. dietary guidelines regarding alcohol consumption risks.

These studies collectively highlight ongoing medical research into prescription drug safety, cardiovascular health interventions, and public health concerns related to food and substance consumption patterns.